



[ampliatx.com](https://ampliatx.com)

# 2022 Year in Review and Growth Plans for 2023

December 2022





# Important Notice and Disclaimer

This presentation (**Presentation**) contains summary information about Amplia Therapeutics Limited ACN 165 160 841 and its subsidiaries (the **Company** or **Amplia**) which is current as at 16 December 2022. By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below.

**Summary Information:** This Presentation has been prepared for information purposes only and is a summary only. It should be read in conjunction with Amplia's most recent financial report and other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which is available at [www.asx.com.au](http://www.asx.com.au). Subject only to any legal obligation to do so, the Company does not have any obligation to correct or update the content of this Presentation.

**Not financial product advice:** This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon as such. This Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (or any other law). It is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction.

**Investment risk and past performance:** An investment in Amplia shares is subject to known and unknown risks, some of which are beyond the control of the Company and its directors. The Company does not guarantee any particular rate of return or the performance of Amplia. Past performance is not, and should not be relied on as being, indicative of future performance.

**Future performance and forward-looking statements:** This Presentation includes forward looking statements, which can generally be identified by the use of words such as "may", "will", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. They may include, without limitation, statements regarding plans, strategies and objectives and anticipated business developments. Forward-looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause Amplia's actual results, performance and achievements to differ materially from statements in this Presentation. Forward-looking statements are based on the Company's good faith assumptions as to the financial,

market, regulatory and other relevant environments that will exist and affect Amplia's business and operations in the future. The Company does not give any assurance that the assumptions will prove to be correct. There may be other factors that could cause actual results or events not to be as anticipated, and many events are beyond the reasonable control of the Company. Readers are cautioned not to place undue reliance on forward-looking statements, **particularly in the current economic climate and given the significant volatility, uncertainty and disruption caused by the COVID-19 pandemic**. Forward-looking statements in this Presentation are only made as at the date of this Presentation and the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

**Industry data and third party information:** Industry data and third party information used in this Presentation may have been obtained from research, surveys, reports or studies conducted by third parties, including industry or general publications. Neither Amplia nor its representatives have independently verified any such market or industry data.

**Financial Information:** This Presentation contains historical financial information based on the Company's results for the 12 month period ending 31 December 2022. All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding.

**Disclaimer:** To the maximum extent permitted by law, Amplia and its officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Amplia or that a prospective investor or purchaser may require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any forward-looking statement.



# Milestones accomplished in 2022



- Commenced recruitment of patients for ACCENT trial in Pancreatic Cancer

- Recruitment for first cohort of patients completed



- Demonstrated increased survival in pre-clinical Pancreatic Cancer model

- Completed 90 day toxicology study to support 3 month clinical dosing

- Positive results in comparison with market leader in pre-clinical pulmonary fibrosis model



- Positive results of second FAK inhibitor, AMP886, in preclinical model of acute myeloid leukemia



# Pancreatic Cancer



## ACCENT Clinical Trial

- **Apr:** Received HREC approval
- **May:** Pre-IND meeting completed
- **Aug:** First patient recruited
- **Sep:** ACCENT trial presented at AACR
- **Nov:** First dosing cohort recruitment complete

## Pre-clinical Studies

- **Feb:** Increased survival demonstrated in human pancreatic cancer model

## Chemistry, Manufacturing, Controls

- **Jul:** Completed manufacture of 5kg batch of AMP945 demonstrating that scale up could be achieved
- **Feb:** Completed manufacture of first batch of capsules
- **May:** Completed manufacture of remaining capsules required for trial



# IPF

## Idiopathic Pulmonary Fibrosis



### Toxicology Studies

- **Aug:** Completed 90 day toxicology studies that support chronic dosing studies for up to 3 months

### Pre-clinical Studies

- **Jul:** AMP945 shown to be as effective as current market leader Ofev<sup>®</sup> (nintedanib) in industry-standard model of IPF


### Chemistry, Manufacturing, Controls

- **Aug:** Manufactured sufficient capsules for a 3 month clinical trial



# AML

## Acute Myeloid Leukaemia



### Pre-clinical Studies

- **Oct:** AMP886, a second FAK inhibitor, was shown to inhibit acute myeloid leukemia (AML) in an industry-standard model of disease

### Chemistry, Manufacturing, Controls

- **Aug:** Sufficient AMP886 has been manufactured for pre-clinical studies



# New Team Members

We have continued to grow the Amplia Team to increase our expertise across the breadth of pre-clinical and clinical studies, and manufacturing



**Chris Burns**

CEO and Managing  
Director

November 2022



**Anthony Bishop**

Principal Development  
Manager

February 2022



**Terrie-Anne Cock**

Head of Translational  
Biology

July 2022



**Adrian Sulistio**

CMC Project Manager

May 2022



# Growth Plans for 2023



- Complete dose selection for ACCENT Trial
- Commence Part B of ACCENT Trial
- Commence process improvement for manufacturing
- Submit IND to US FDA
- Progress towards a second clinical trial with AMP945
- Continue to progress the development of AMP886





# Thank You.

Amplia Therapeutics Limited

ABN 16 165 160 841

ASX: ATX

[info@ampliatx.com](mailto:info@ampliatx.com)

[ampliatx.com](http://ampliatx.com)



Dr Chris Burns  
Chief Executive Officer  
[chris@ampliatx.com](mailto:chris@ampliatx.com)